| Patient | Nelson Mandela |
|---|---|
| Date of birth | 1918-07-18 |
| Identifiers | MRN HR-ML021-SYN-TD; SSN (made up) 000-21-6718 |
| Document date | 2001-04-14 |
| Author | Thandiwe Mokoena, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Five-week follow-up after the prostate cancer diagnosis; staging result; radiation oncology seen today. [S]
Mr. Mandela returns five weeks after his first visit. The PSMA PET/CT two weeks ago showed uptake only in the prostate, with no spread to lymph nodes or bone. He had his DXA scan this morning and then saw Dr. van Zyl of radiation oncology, who went through observation, radiotherapy with short-term androgen deprivation, and surgery with him. He chose radiotherapy to the prostate with six months of androgen deprivation. He starts bicalutamide today and will have his first leuprolide injection at the radiation oncology clinic in one week. Before starting, he was told the expected effects of androgen deprivation (hot flashes, tiredness, loss of libido and erections, weight gain, bone loss, and changes in mood or memory) and how they are monitored. His urinary symptoms are unchanged and mild. He has no bone pain, weight loss, or breathlessness. He starts vitamin D today for the low level found at the first visit. [S]
| Element | Detail |
|---|---|
| Staging | PSMA PET/CT: disease confined to the prostate (N0 M0) |
| Decision | Radiotherapy with six months of androgen deprivation, after radiation oncology consultation today |
| Starting today | Bicalutamide 50 mg daily for four weeks; cholecalciferol 1000 units daily |
| Next step | First leuprolide injection in one week at radiation oncology |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fatigue, weight loss, or night sweats |
| Genitourinary | Positive | Mild urinary frequency, unchanged; no blood in the urine |
| Musculoskeletal | Negative | No bone or back pain |
| Respiratory | Negative | No cough or breathlessness |
| Psychiatric | Negative | Mood good; PHQ-2 score 0 |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Bicalutamide 50 mg oral tablet, one tablet by mouth once daily for four weeks, to block the testosterone flare at the start of leuprolide | One tablet once daily for four weeks | Oral route | 2001-04-14 to 2001-05-12 | completed | S |
| Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily | One tablet once daily | Oral route | 2001-04-14 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2001-04-14 | Body height | 183 | cm | S |
| 2001-04-14 | Body weight | 80.4 | kg | S |
| 2001-04-14 | Body mass index (BMI) [Ratio] | 24 | kg/m2 | S |
| 2001-04-14 | Systolic blood pressure | 130 | mm[Hg] | S |
| 2001-04-14 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2001-04-14 | Heart rate | 66 | /min | S |
| 2001-04-14 | Respiratory rate | 14 | /min | S |
| 2001-04-14 | Body temperature | 36.7 | Cel | S |
| 2001-04-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2001-04-14 | DXA Femur [T-score] Bone density | -1.4 | {T-score} | -1.0 or higher is normal; -2.5 or lower is osteoporosis | Low | S |
| 2001-04-14 | DXA Lumbar spine [T-score] Bone density | -0.6 | {T-score} | -1.0 or higher is normal; -2.5 or lower is osteoporosis | Normal | S |
| 2001-04-14 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S |
Vital signs recorded on 2001-04-14; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well |
| Cardiovascular | Regular rhythm; blood pressure 130/76 mm Hg; no ankle swelling |
| Abdomen | Soft; bladder not palpable |
| Musculoskeletal | No spinal tenderness |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Adenocarcinoma of the prostate, NCCN unfavorable intermediate risk: cT1c, Grade Group 3 (Gleason 4+3), PSA 6.4 ng/mL, 3 of 14 cores, found after a rising PSA; synthetic modern detail linked to his publicly announced prostate cancer | active | confirmed | C61 | S — Synthetic grade, PSA, core count, stage, and risk group; the PSA rise, the biopsy-proven localized cancer that was not high grade, hormone therapy, and curative radiotherapy are from his doctors' and spokeswoman's public statements (D). |
| Hormone-sensitive prostate cancer | active | confirmed | Z19.1 | S — Synthetic status in the modern episode. |
| Short-term androgen deprivation therapy (six months, leuprolide), with monitoring of testosterone, bone density, metabolic and cardiovascular risk, hot flashes, mood, and cognition | active | confirmed | Z79.899 | S — Synthetic androgen deprivation plan; Z79.899 is used because ICD-10-CM has no specific code for GnRH agonist therapy. |
| History of pulmonary tuberculosis, treated, with no symptoms since | resolved | confirmed | Z86.11 | S — The 1988 tuberculosis is documented (D); the coding and the statement that it has not recurred are synthetic. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | PSA before treatment | At diagnosis, then every 3 to 6 months on androgen deprivation | Up to date | 6.4 ng/mL at the first visit; next on androgen deprivation in three months |
| Laboratory | Testosterone | Baseline, then every 3 to 6 months on androgen deprivation (target below 50 ng/dL) | Up to date | 412 ng/dL at the first visit, before treatment; recheck in three months |
| Laboratory | Hemoglobin A1c or fasting glucose, and lipid panel | Baseline and yearly on androgen deprivation | Up to date | A1c 5.5 percent, glucose 94 mg/dL, LDL 112 mg/dL at the first visit; next in one year |
| Laboratory | Calcium and 25-hydroxyvitamin D | Baseline and periodically on androgen deprivation | Due | Calcium 9.4 mg/dL and vitamin D 26 ng/mL at the first visit; supplement starts today; vitamin D recheck in three months |
| Imaging | Bone density (DXA) | Baseline before androgen deprivation, then every 1 to 2 years | Completed today | Femoral neck T-score -1.4 (low bone mass); lumbar spine -0.6 (normal); hip fracture risk below the treatment threshold |
| Imaging | PSMA PET/CT staging | Once, for unfavorable intermediate or high risk | Up to date | Two weeks ago: no nodal, bone, or visceral disease |
| Examination | Blood pressure and cardiovascular assessment | Every visit on androgen deprivation | Completed today | 130/76 mm Hg; no chest pain or breathlessness; baseline before treatment |
| Survey | Distress and depression screen (PHQ-2) | At diagnosis and at intervals | Completed today | PHQ-2 score 0 |
| Survey | Urinary symptoms (IPSS) | Baseline before treatment, then every follow-up visit | Up to date | IPSS 7 (mild) at the first visit; no change today |
| Survey | Sexual function | Baseline before treatment and periodically | Completed today | Reviewed before androgen deprivation; the expected effects were explained |
| Survey | Cognition | Periodically on androgen deprivation | Due | Cognitive screen at the annual wellness visit in about eight weeks |
| Medication safety | Hot flashes and fatigue | Every visit on androgen deprivation | Not indicated | Androgen deprivation not yet started; counseled on what to expect |
| Medication safety | Testosterone flare protection | When starting a GnRH agonist | Completed today | Bicalutamide starts today, one week before leuprolide, and continues for four weeks |
| Referral | Radiation oncology | Once, then through treatment | Completed today | Seen today; recommendations in the consultation note |
| Self-management | Physical activity, calcium intake, and no tobacco | Every visit | Completed today | Walking every morning; resistance exercise added; dietary calcium reviewed |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026); Eastham JA, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management. J Urol 2022;208(1):10-18 (2022); Skolarus TA, et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin 2014;64(4):225-249 (2014); CMID: Clinical Monitoring Intelligence Database, prostate cancer monograph (2026)
Follow-up: Leuprolide at radiation oncology in one week. Annual wellness visit in eight weeks. Primary care follow-up in three months with PSA, testosterone, and vitamin D. Next scheduled visit 2001-06-09: subsequent annual wellness visit. [S]